Home > Insider Trading > Filing (0001104659-22-025736)

Filing Details

Accession Number:: 0001104659-22-025736
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-02-22 17:22:21
Reporting Period:: 2022-02-17

Accepted Time:: 2022-02-22 17:22:21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1831915	Cytek Biosciences Inc.	CTKB	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1315082	Ra Capital Healthcare Fund Lp	200 Berkeley Street 18Th Floor Boston MA 02116	Yes	No	No	No
1346824	Ra Capital Management, L.p.	200 Berkeley Street 18Th Floor Boston MA 02116	Yes	No	No	No
1384859	Peter Kolchinsky	C/O Ra Capital Management, L.p. 200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	No	No
1619841	M. Rajeev Shah	C/O Ra Capital Management, L.p. 200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	No	No
1825376	Ra Capital Nexus Fund Ii, L.p.	200 Berkeley Street 18Th Floor Boston MA 02116	Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-02-17	166,229	$14.78	10,271,886	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2022-02-18	166,229	$14.12	10,438,115	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2022-02-22	214,922	$13.46	10,653,037	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Footnotes

The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established December 14, 2021.
This transaction was executed in multiple trades at prices ranging from $14.50 to $15.39; the price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
These securities include 8,578,395 shares held directly by RA Capital Healthcare Fund, L.P. (the "Fund"), 1,185,767 shares held by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and 507,724 shares held by a separately managed account (the "Account").
This transaction was executed in multiple trades at prices ranging from $13.63 to $14.79; the price reported above reflects the weighted average purchase price.
These securities include 8,744,624 shares held directly by the Fund, 1,185,767 shares held by Nexus Fund II, and 507,724 shares held by the Account.
This transaction was executed in multiple trades at prices ranging from $12.89 to $13.76; the price reported above reflects the weighted average purchase price.
These securities include 8,959,546 shares held directly by the Fund, 1,185,767 shares held by Nexus Fund II, and 507,724 shares held by the Account.
RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.